Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CURx Pharmaceuticals Inc.

www.curxpharma.com

Latest From CURx Pharmaceuticals Inc.

Zavante Targets Resistant Urinary Infections With I.V. Version Of Existing Drug

If approved, Zolyd will be the first intravenous epoxide antibiotic approved in the US, with greater potency than the oral version used first-line. Ex-US, the I.V. formulation has demonstrated a stable resistance profile.

Infectious Diseases Clinical Trials

Deals Shaping The Medical Industry, March 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January through February 2014.

BioPharmaceutical Medical Device

Deals Of The Week: Novartis Places Bid To Dominate In Cancer

Novartis beefs up its immunotherapy pipeline, while French biotech Servier makes a play to get in the CART game. Yet, the deal on everybody’s lips is Actavis’ acquisition of Forest. Plus news on Gilead and Pfizer.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, October 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced August through September 2013.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • CURx Pharma
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • CURx Pharmaceuticals Inc.
  • Senior Management
  • Dinu Sen, CEO
    Jeff McKelvy, MD, PhD, CSO
  • Contact Info
  • CURx Pharmaceuticals Inc.
    3210 Merryfield Row
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register